Legal Representation
Attorney
Jeremy Blackowicz
USPTO Deadlines
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 16, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 16, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 10, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 29, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 19, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 19, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 19, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 19, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 19, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 18, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 18, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 18, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 14, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 13, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 2, 2025 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 1, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 26, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 16, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 16, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 13, 2025 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of autoimmune conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of blood conditions, diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; pharmaceutical preparations for the prevention and treatment of dermatological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of endocrine conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of hepatic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of immunological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of infectious diseases; pharmaceutical preparations for the prevention and treatment of inflammatory conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of metabolic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of muscular conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of neurological conditions, diseases, and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the prevention and treatment of psychiatric conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of respiratory and pulmonary conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of renal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of urological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of viral diseases.
Classification
International Classes
005